Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25383397 | 0.98 | L3MBTL1 (0.95) | L3MBTL1ALDH1A1MAPTPOLBCYP1A2 | |
| Hydrochloric Acid SCHEMBL2674470 | 0.98 | L3MBTL1 (0.95) | L3MBTL1ALDH1A1MAPTPOLBCYP1A2 | |
| SCHEMBL1007439 | 0.98 | L3MBTL1 (0.95) | L3MBTL1ALDH1A1MAPTPOLBCYP1A2 | |
| Hydrochloric Acid SCHEMBL2673561 | 0.95 | L3MBTL1 (0.91) | L3MBTL1ALDH1A1MAPTPOLBCYP1A2 | |
| Bromide SCHEMBL5330234 | 0.95 | L3MBTL1 (0.91) | L3MBTL1ALDH1A1MAPTPOLBCYP1A2 | |
| SCHEMBL493879 | 0.88 | L3MBTL1 (0.79) | L3MBTL1ALDH1A1MAPTPOLBCYP1A2 | |
| SCHEMBL11598668 | 0.87 | L3MBTL1 (0.77) | L3MBTL1ALDH1A1MAPTPOLBCYP1A2 | |
| SCHEMBL8860545 | 0.87 | L3MBTL1 (0.77) | L3MBTL1ALDH1A1MAPTPOLBCYP1A2 | |
| Hydrochloric Acid SCHEMBL2710255 | 0.86 | L3MBTL1 (0.76) | L3MBTL1ALDH1A1MAPTPOLBCYP1A2 | |
| SCHEMBL3904815 | 0.86 | L3MBTL1 (0.76) | L3MBTL1ALDH1A1MAPTPOLBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368650-A1 | 5-(4-FLUOROPHENYL)-2,3-DIHYDRO-1H-IMIDAZO[1,2-A]IMIDAZOLE DERIVATIVES AS ALK INHIBITORS FOR THE TREATMENT OF FIBROSIS | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-12-04 | — | — | US | claimed |
| WO-2025003545-A1 | DERIVATIVES OF IMIDAZO[1,2-A]PYRIDINE WITH ANTI-INFLAMMATORY ACTIVITY | UNIVERSITAT DE VALÈNCIA (ES) | 2025-01-02 | — | — | WO | claimed |
| US-20240199679-A1 | ADENOSINE DERIVATIVE HAVING ANTAGONISTIC ACTION ON A2A AND A3 ADENOSINE RECEPTORS AND METHOD FOR PREPARING SAME | FUTURE MEDICINE CO., LTD. (KR) | 2024-06-20 | — | — | US | claimed |
| US-11993609-B2 | Compositions and methods for oral delivery of crystalline PRX-3140 potassium salt | Nanopharmaceutics, Inc. (US) | 2024-05-28 | — | — | US | claimed |
| EP-4296273-A1 | ADENOSINE DERIVATIVE HAVING ANTAGONISTIC ACTION ON A2A AND A3 ADENOSINE RECEPTORS AND METHOD FOR PREPARING SAME | Future Medicine Co., Ltd. (KR) | 2023-12-27 | — | — | EP | claimed |
| WO-2023235166-A1 | CRYSTALLINE 6,7-DIHYDRO-4-HYDROXY-7-ISOPROPYL-6-OXO-N-(3-(PIPERIDIN-1-YL)PROPYL)THIENO[2,3-B]PYRIDINE-5-CARBOXAMIDE POTASSIUM SALT (PRX-3140) FOR PARTICLE DELIVERY SYSTEMS (PDS) | Nanopharmaceutics, Inc. (US) | 2023-12-07 | — | — | WO | claimed |
| US-20230391791-A1 | Compositions And Methods For Oral Delivery Of Crystalline PRX-3140 Potassium Salt | Nanopharmaceutics, Inc. (US) | 2023-12-07 | — | — | US | claimed |
| CN-117083286-A | Pair A 2A A is a 3 Adenosine derivatives having antagonism to adenosine receptor and process for preparing same | 未来制药有限公司 | 2023-11-17 | — | — | CN | claimed |
| CN-116157124-A | Sulfonamide derivative and pharmaceutical composition for preventing or treating mental diseases containing the same as active ingredient | 大邱庆北尖端医疗产业振兴财团 | 2023-05-23 | — | — | CN | claimed |
| WO-2022203427-A1 | ADENOSINE DERIVATIVE HAVING ANTAGONISTIC ACTION ON A2A AND A3 ADENOSINE RECEPTORS AND METHOD FOR PREPARING SAME | 퓨쳐메디신 주식회사 | 2022-09-29 | — | — | WO | claimed |
| WO-2002012242-A2 | BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PHARMACIA ITALIA S.P.A. (IT) | 2002-02-14 | — | — | WO | claimed |
| EP-0682663-B1 | 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS | UPJOHN CO (US) | 2001-04-18 | — | — | EP | claimed |
| US-5958950-A | CARDIOVASCULAR DISORDERS | WARNER-LAMBERT COMPANY (US) | 1999-09-28 | — | — | US | claimed |
| WO-1998025884-A1 | FURTHER ANTHRAQUINONES WITH BIOLOGICAL ACTIVITY | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1998-06-18 | — | — | WO | claimed |
| EP-0830349-A1 | METHOD FOR PREPARING N, N'-DISUBSTITUED CYCLIC UREAS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-03-25 | — | — | EP | claimed |
| US-5686486-A | 4-hydroxy-benzopyran-2-ones and 4-hydroxy-cycloalkyl b!pyran-2-ones useful to treat retroviral infections | PHARMACIA & UPJOHN COMPANY (US) | 1997-11-11 | — | — | US | claimed |
| WO-1996039393-A1 | METHOD FOR PREPARING N, N'-DISUBSTITUED CYCLIC UREAS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-12-12 | — | — | WO | claimed |
| EP-0691961-A1 | SUBSTITUTED CAPROLACTAMS AND DERIVATIVES THEREOF USEFUL FOR TREATMENT OF HIV DISEASE | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-01-17 | — | — | EP | claimed |
| EP-0682663-A1 | 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 1995-11-22 | — | — | EP | claimed |
| WO-1994018188-A1 | 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL[B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS | THE UPJOHN COMPANY (US) | 1994-08-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391791-A1 | Compositions And Methods For Oral Delivery Of Crystalline PRX-3140 Potassium Salt | KCNK10, CHRNA10, PRNP | L3MBTL1 4820/4885ALDH1A1 4092/4885MAPT 19/4885 |
| US-11993609-B2 | Compositions and methods for oral delivery of crystalline PRX-3140 potassium salt | KCNK10, CHRNA10, PRNP | L3MBTL1 4820/4885ALDH1A1 4092/4885MAPT 19/4885 |
| US-20250368650-A1 | 5-(4-FLUOROPHENYL)-2,3-DIHYDRO-1H-IMIDAZO[1,2-A]IMIDAZOLE DERIVATIVES AS ALK INHIBITORS FOR THE TREATMENT OF FIBROSIS | ALK, TGFBR2, TGFBR1 | L3MBTL1 4590/4885ALDH1A1 479/4885MAPT 3438/4885 |
| US-20240199679-A1 | ADENOSINE DERIVATIVE HAVING ANTAGONISTIC ACTION ON A2A AND A3 ADENOSINE RECEPTORS AND METHOD FOR PREPARING SAME | ADORA2A, ADORA3, ADORA2B | L3MBTL1 4129/4885ALDH1A1 978/4885MAPT 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.